Large molecule therapeutics, such as antibodies and other protein-based drugs, has become the major modality of oncology treatments. Discovery and development of drug candidates require detailed characterization of the candidates in pharmacokinetics (PK) and potential toxicity (Tox, also known as safety assessment) in designated animal species, a process called preclinical development. Understanding of PK and Tox is essential for the advancement of the candidates intoclinical trials.
The LMPD core, funded by the Cancer Prevention and Research Institute of Texas (CPRIT) is a joint operation of the Brown Foundation Institute of Molecular Medicine (IMM) of the University of Texas Health Science Center at Houston (UTHealth) and the Michale E. Keeling Center for Comparative Medicine and Research (KCCMR) of the University of Texas MD Anderson Cancer Center. Our mission is to provide preclinical development support free of charge to cancer researchers at Texas, including scale up production and characterization of drug candidates, PK and Tox analysis in two animal species, and in vivo imaging and biodistribution.
See Our Services
